Interferon (INF)-Free Antiviral Therapy in Cirrhotic Patients Infected with Hepatitis C on the Waiting List for Liver Transplantation. Efficacy and Impact on Delisting and Liver Function

Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end‐stage liver disease: Analysis of data from the Hepa‐C registry

“…A major concern in liver transplant candidates is that attainment of SVR may not be associated with sufficient improvement in liver function to allow patients to live well without transplantation, or to reduce the risk of HCC . In two recent studies, some listed patients on IFN‐free treatment could be delisted . It is noticeable that patients with baseline MELD 16‐20 had a higher probability of being delisted than those with MELD >20 in one study, and that no patient with MELD >18 was delisted in the other study .…”

“…In two recent studies, some listed patients on IFN‐free treatment could be delisted . It is noticeable that patients with baseline MELD 16‐20 had a higher probability of being delisted than those with MELD >20 in one study, and that no patient with MELD >18 was delisted in the other study . These observations seem to be in accordance with our study and suggest that, if treated, patients with high MELD scores may be deprioritized on the transplant list owing to a discrete MELD reduction without real clinical improvement.…”

IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting

“…31 -33 Coilly et al 33 showed that 36% of treated patients with decompensated cirrhosis experienced clinical improvement and 16% were delisted. Similar results were observed by Belli et al 31 and Pascasio et al, 32 where 20% of the patients were delisted after effective antiviral therapy. In HIV/ HCV-coinfected patients, Llaneras et al 34 reported the case of one patient delisted after viral eradication with sofosbuvir and daclatasvir.…”

The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver

“…However, we suggest that patients with Model for Endstage Liver Disease (MELD) scores above 15 to 18 may bene fit from deferral of therapy. [66][67][68][69][70] Patients with decompensated cir rhosis should be evaluated in centres that have experience with endstage liver disease because of the risk of worsening decom pensation during therapy. Specific recommendations for treat ment of decompensated cirrhosis are presented in Appendix 1.…”